trending Market Intelligence /marketintelligence/en/news-insights/trending/PpyBaDbOTUov0kH_1sRlaw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Mylan recalls 2 batches of cancer-related injection

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Mylan recalls 2 batches of cancer-related injection

Pennsylvania-based generic-drug maker Mylan NV has voluntarily recalled two U.S.-distributed batches of its Levoleucovorin injection due to copper salt particles found in the drug.

The recall, initiated as a result of annual stability testing, is being conducted through the company's Illinois subsidiary Mylan Institutional Inc.

Levoleucovorin injection is used to treat toxicity associated with cancer drugs such as methotrexate and chemotherapy. The batches of 250-milligram ingredient in 25 mL vials were distributed in the U.S. between August 2017 and July 2018, according to Mylan.

No adverse events have been reported as a result of the contamination, but the presence of particulates could lead to problems such as irritation, allergic reactions and more.

The company urged wholesalers, retailers and consumers to examine their stock of the drug for the batches.

Another of Mylan's drugs, the blood pressure drug valsartan, has been among the subjects of another recall since July 2018 due to the presence of possible carcinogens in one of its ingredients originating in China.